Cellceutix Plans for Future Trials Aimed at the Latest Initiatives of ‘Breakthrough’ Designation by the Food and Drug Administration

Beverly, MA – Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, is pleased to report that Kevetrin™, the Company’s lead anti-cancer compound currently in a Phase 1 clinical trial at Harvard Cancer Center for solid tumors, has shown to be effective against animal models of retinoblastoma.

Retinoblastoma is a rare and serious disease in which cancer cells grow in the retina of the eye.  According to the American Cancer Society, less than 300 children are diagnosed with retinoblastoma each year in the United States.  It is the most common type of eye cancer in children and accounts for 6 percent of all cancers in children under the age of five.  It is most frequently diagnosed in infants and very young children; the average age of children when they are diagnosed is 2.  (www.cancer.org/cancer/retinoblastoma)

Current therapies are difficult to tolerate especially in children, e.g., removal of the eye, intense radiation therapy, or chemotherapy given either systemically or locally in the eye, and are limited in their effectiveness. The need for an effective therapy against retinoblastoma is urgently needed.

The Company conducted pre-clinical studies using human retinoblastoma cells (WERI-Rb-1) in nude mice that were implanted either subcutaneously or directly into the eye, intravitreally. Treatment with Kevetrin significantly reduced the tumor volume by more than half in the subcutaneous tumor model and showed a significant improvement in the clarity of the eye in mice treated with Kevetrin as shown in the photographs below and on our website at www.cellceutix.com/kevetrin.

Given the limited treatment options, devastating effects, and small patient population, Cellceutix believes that retinoblastoma would make an excellent candidate for a phase 2/3 trial once our present phase 1 trial is completed. It would qualify for a number of FDA programs (Orphan, Fast Track and Breakthrough) that can exponentially shrink development time, should clinical data support the current research.

“While our Phase 1 clinical trial is ongoing, we are planning for future trials that are aimed directly at the latest initiatives of the Food and Drug Administration to expedite development of ‘breakthrough’ technologies to commercialization,” commented Dr. Krishna Menon, Chief Scientific Officer at Cellceutix.  “The data from the studies affirm that Kevetrin may be useful in a new tumor type, in addition to the other indications that we are studying. Kevetrin has delivered robust results against all indications tested to date.  Cellceutix’s strategy is to have multiple trials ongoing against multiple cancer types concurrently.  We are conducting testing against several more cancers to delineate the quickest path to market to build corporate and shareholder value.”

Further information on the clinical trial, titled “A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors,” is available at: http://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=1